Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma

International Journal of Cancer

Volumn 102, Issue 4, 2002, Pages 372-378

  Diesinger, Isabel ^a   Bauer, Christine ^a   Brass, Nicole ^a   Schaefers, Hans Joachim ^a   Comtesse, Nicole ^a   Sybrecht, Gerhard ^a   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Autologous sera; Heterologous sera; Lung cancer; SEREX

Indexed keywords

BINDING PROTEIN; LYMPHOID BLAST CRISIS PROTEIN; PROTEIN; PROTEIN KINASE C; PROTEIN P53; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CHROMOSOMAL LOCALIZATION; CHROMOSOME MAP; CONTROLLED STUDY; DATA BASE; DNA LIBRARY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LARGE CELL CARCINOMA; LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CHROMOSOME MAPPING; DNA, NEOPLASM; GENE LIBRARY; HUMANS; LUNG NEOPLASMS;

EID: 0036888301     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10714     Document Type: Article

References (43)

1. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: Autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433-40.
2. Sanchez-Carbayo M, Chulia MT, Nivjeiro M, Aranda I, Mira A, Soria F. Autoantibodies against p53 protein in patients with transitional cell carcinoma of the bladder. Anticancer Res 1999;19:3531-7.
3. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrascharan K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
4. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomon M, Diamandis EP. Circulating antibodies against p53 protein in patients with ovarian carcinomas: Correlation with clinicopathologic features and survival. Cancer 1996;78:2146-52.
5. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 1998;77: 1848-51.
6. Porzolt FMS, Hoher D, Mude D, Gaus W, Montenarh M. Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 1994;17:402-8.
7. Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F, Kohiyama M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991;47:665-9.
8. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997;25:75-80.
9. Blanke CD, Johnson DH, Combined modality therapy in non-small cell lung cancer. Curr Opin Oncol 1995:7:144-9.
10. Wild CP, Ridanpää M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K, et al. p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue. Int J Cancer 1995;64:176-81.
11. Zalcman G, Trédaniel G, Schlichtholz B, Urban T, Milleron B, Lubin R, et al. Prognostic significance of serum p53 antibody in patients with limited-stage small cell lung cancer. Int J Cancer 2000;89:81-6.
12. Yamamoto A, Shimizu E, Sumitoma K, Shinohara A, Namikawa O, Uehara H, et al. L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and the pleural effusion from a patient with non-small cell lung cancer. Intern Med 1997;36:724-7.
13. Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, et al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999; 56:129-33.
14. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese E. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001;92:822-9.
15. Obata Y, Takahashi T, Sakamoto J, Tamaki H, Tominaga S, Hamajima N, et al. SEREX analysis of gastric cancer antigens. Cancer Chemother Pharmacol 2000;46(Suppl):S37-42.
16. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999;83:456-64.
17. Gure AO, Stockert E, Scanlan MJ, Keresztes RS, Jager D, Altorki NK, et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci USA 2000;97:4198-203.
18. Tureci O, Sahin U, Zwick C, Neumann F, Pfreundschuh M. Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma 1999;18:23-8.
19. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001;98:629-34.
20. Brass N, Rácz A, Bauer C, Heckel D, Sybrecht G, Meese E. Role of amplified genes in the production of autoantibodies. Blood 1999;93: 2158-66.
21. Scanlan MJ, Chen Y-T, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci Ö, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
22. Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000;69:254-8.
23. Schwartz MA, Toksoz D, Khosravi-Far R. Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin-dependent pathway. EMBO J 2000;15:6525-30.
24. Wang XY, Repasky E, Liu HT. Antisense inhibition of protein kinase Ca reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 1999;250:253-63.
25. Chen CF, Chen Y, Dai K, Chen PL, Riley DJ, Lee WH. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol Cell Biol 1996;16:4691-9.
26. Kumar R, Haugen JD, Wieben ED, Londowski JM, Cai Q. Inhibitors of renal epithelial phosphate transport in tumor-induced osteomalacia and uremia. Proc Assoc Am Physicians 1995;107:296-305.
27. Mori T, Okamoto H, Takahashi N, Ueda R, Okamoto T. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett 2000;465:124-8.
28. Lietard J, Musso O, Theret N, L'Helgoulac'h A, Campion JP, Yamada Y, et al. Sp1-mediated transactivation of LamC1 promoter and coordinated expression of laminin-gamma1 and Sp1 in human hepatocellular carcinomas. Am J Pathol 1997; 151:1663-72.
29. Hazen LG, Bleeker FE, Lauritzen B, Bahns S, Song J, Jonker A, et al. Comparative localization of cathepsin B protein and activity in colorectal cancer. J Histochem Cytochem 2000;48:1421-30.
30. Werle B, Lotterle H, Schanzenbacher U, Lah TT, Kalman E, Kayser K, et al. Immunochemical analysis of cathepsin B in lung tumors: An independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 1999;81:510-9.
31. Fernandez-Madrid F, Karvonen RL, Kraut MJ, Czelusniak B, Ager JW. Autoimmunity to collagen in human lung cancer. Cancer Res 1996;56:121-6.
32. Kettunen E, el-Rifai W, Bjorkqvist AM, Wolff H, Karjalainen A, Anttila S, et al. A broad amplification pattern at 3q in squamous cell lung cancer - A fluorescence in situ hybridization study. Cancer Genet Cytogenet 2000;117:66-70.
33. Sugita M, Tanaka N, Dabidson S, Sekiya S, Varella-Garcia M, West J, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet 2000;117:9-18.
34. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 1997;6:33-9.
35. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 1997;57:2331-5.
36. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894-906.
37. Merlo A, Gabrielson E, Mabry M. Vollmer R, Baylin SB, Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 1994;54:2322-6.
38. Stanton SE, Shin SW, Johnson BE, Meyerson M. Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. Genes Chromosomes Cancer 2000:27:323-31.
39. De Juan C, Iniesta P, Cruces J, Sanchez A, Massa MJ, Gonzalez-Quevendo R, et al. DNA amplification on chromosome 6p12 in non small cell lung cancer detected by arbitrarily primed polymerase chain reaction. Int J Cancer 1999;84:344-9.
40. Zhou JY, Taguchi T, Siegfried JM, Jhanwar SC, Resau J, Testa JR. Characterization of 9q;15q whole-arm translocation derivatives in non-small cell lung carcinomas by fluorescence in situ hybridization. Cancer Genet Cytogenet 1993;69:1-6.
41. Bergqvist AS, Bergqvist M, Brattstrom D, Hesselius P, Larsson A, Brodin O, Wagenius G. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001; 21:4141-5.
42. Vogl FD, Frey M, Kreienberg R, Runnenbaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
43. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUCI is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000;161: 589-94.